Report links interest in Teva's generics assets from Novartis and Mylan

16 May 2016
mergers-acquisitions-big

The assets of Israeli drugmaker Teva Pharmaceutical International (NYSE: TEVA) in the UK, Ireland and Iceland) have attracted interest from bidders including Netherlands-incorporated Mylan (Nasdaq: MYL) and Swiss pharma giant Novartis (NOVN: VX), Bloomberg reports.

Insiders quoted by Bloomberg report that private equity firms Apollo Global Management and Cinven are also weighing up making bids for the business, which could cost $1.5 billion to $2 billion.

It is understood that the European Commission would prefer the assets to go to a buyer with experience in Europe’s generics market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics